CAIRE Inc. has acquired Spirosure, Inc. to expand CAIRE’s portfolio into the diagnostic segment of respiratory care.
Spirosure is a California-based developer and manufacturer of an innovative technology for measuring fractional exhaled nitric oxide, which is a key indicator of allergic inflammation in asthmatic patients.
Spirosure will operate as a division of Georgia, US-based CAIRE to be known as CAIRE Diagnostics Inc.
Japan-based NGK Spark Plug Co., Ltd. acquired CAIRE in December 2018 to establish a global foothold in the respiratory therapy business and had previously invested in Spirosure as the latter company’s technology was in development.
“We are very pleased to have found an excellent strategic buyer in CAIRE through one of our key investors,” said Solomon Ssenyange, PhD, CEO and Chairman of Spirosure.
“CAIRE shares our commitment to technological leadership and, with its large international organisation, is well-positioned to realise the full potential of our proprietary technology both commercially and with regard to our development pipeline. We look forward to an exciting future as part of CAIRE.”
Spirosure recently launched its first product to market, the Fenom Pro®, a reliable and convenient to use device that accurately measures fractional exhaled nitric oxide at parts-per-billion levels using a proprietary sensor technology. The product is intended to be used in the clinic setting and is currently available in the US, the EU and India.
CAIRE, a global manufacturer of oxygen supply equipment, has a portfolio marketed under the AirSep®, CAIRE®, HELiOS™ and SeQual® brands, which includes portable and stationary oxygen therapy devices and turnkey on-site generation commercial solutions.